Skip to main content
. 2011 Oct 7;6:2235–2244. doi: 10.2147/IJN.S24720

Figure 3.

Figure 3

Transfection efficiency of polycation lipid nanocarrier/DNA complexes (PDC) (N/P = 10) in human lung adenocarcinoma (SPC-A1) cells compared with those of Lipofectamine™ 2000/DNA complexes (LDC). (A) Transfection efficiency of plasmid pEGFP-N2 determined by flow cytometer; (B) relative luciferase activity in SPC-A1 cells treated with PDC in comparison with that of LDC; (C) the cell viability of PDCs in SPC-A1 cells compared with that of polyethylenimine (PEI)/DNA complexes at various N/P ratios (*P < 0.05, **P < 0.01) (n = 3).